---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-079677"
form_type: "8-K"
ticker: "ADIL"
cik: "0001513525"
company_name: "ADIAL PHARMACEUTICALS, INC."
filed_at: "2023-09-27T23:59:59+00:00"
generated_at: "2026-06-10T08:10:07.174658+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Adial recasts 2022 and 2021 financials to reflect Purnovate discontinued ops after sale

## Summary
- Completed sale of Purnovate assets and business to Adovate, LLC on June 30, 2023.
- Historical Purnovate results now shown as discontinued operations for 2022 and 2021.
- Only Item 7 (MD&A) and Item 8 (Financial Statements) are revised; other 10-K sections unchanged.
- Company directs investors to Q1 and Q2 2023 Form 10-Qs for more recent developments.

## SEC filing metadata
- accession: 0001213900-23-079677
- form_type: 8-K
- ticker: ADIL
- cik: 0001513525
- company_name: ADIAL PHARMACEUTICALS, INC.
- filed_at: 2023-09-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1513525/000121390023079677/0001213900-23-079677-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1513525/000121390023079677/ea185608-8k_adialpharma.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-079677
- JSON: https://secwatch.observer/filing/0001213900-23-079677.json
- Plain text: https://secwatch.observer/filing/0001213900-23-079677.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.